Professor Vladimir Tolmachev of Uppsala University, Sweden, together with his colleagues is giving online lectures for TPU young researchers. In 12 lectures, he is going to present a novel technology to produce diagnostic and therapeutic radiopharmaceuticals using scaffold proteins for tumor targeting.
Photo: TPU team in the project supported by a megagrant (from left to right): Vladimir Chernov, Head of the Department of Radionuclide Diagnostics, Tomsk Cancer Research Institute, Vladimir Tolmachev, Professor of Uppsala University, and Sergey Deev, Head of the Laboratory of Molecular Immunology, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry
Professor Tolmachev heads the TPU project, which was awarded megagrant funding from the Russian government in 2019. These grants support studies supervised by leading international researchers. TPU has already founded the Oncotheranostics Research Center led by Professor Tolmachev. It includes chemists, physicians, biochemists and nuclear medicine specialists, along with those from the Oncology Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Sciences (Moscow).
“Educational activity is one of the Center’s important tasks. Vladimir Tolmachev is an internationally recognized specialist in the field of radiochemistry. He and his colleagues will talk online about the principles of creating scaffold protein-based radiopharmaceuticals.
This is a new technology for the whole world, state of the art. Although it has amazing advantages, it is rarely used worldwide. Such drugs are being developed at TPU and our young researchers have the opportunity to learn about them firsthand,”
Marina Trusova, head of the TPU Research School of Chemistry & Applied Biomedical Sciences, notes.
Vladimir Tolmachev has been studying scaffold proteins for many years. This is a kind of scaffolding for biomedicine based on natural or synthesized protein compounds. They have a peculiar ability to bind to certain areas of tumor cells, i.e. targets. Each scaffold protein is specific for a particular type of tumor cell. If you bind scaffold protein to a radioactive isotope, it will deliver it directly to the target cell. However, binding protein and isotope is an extremely complex task. The TPU researchers proposed to do this using a number of organic compounds also known as linkers.
Currently, the first radiopharmaceutical created as part of the megagrant is undergoing clinical trials at the Oncology Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Sciences.
The next lecture is scheduled for today, June 1, and will cover protein-labeling for PET. The working language is English.
All lectures are recorded. To receive access to the previous ones, please contact Nataliya Viktorovna Remkhe (email@example.com), engineer of the Oncotheranostics Research Center.